Rallybio Secures $2.6 Million in Funding to Advance Life-Transforming Therapies

Rallybio (NASDAQ: RLYB), a pioneering clinical-stage biotechnology company committed to tackling science's most formidable challenges, has announced the successful completion of a funding round, raising $2.6 million. With a focus on developing transformative therapies for patients facing severe and rare diseases, Rallybio is at the forefront of medical innovation. The newly acquired funds will be integral in advancing their robust pipeline of product candidates, which are specifically designed to address pressing unmet needs in maternal-fetal health, complement dysregulation, hematology, and metabolic disorders. Notably, the company is advancing two pivotal clinical-stage programs—RLYB212, aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT), and RLYB116, a complement component 5 (C5) inhibitor targeting complement dysregulation diseases. The financial boost will enable Rallybio to accelerate the progression of these programs through the clinical stages, enhancing their capability to deliver substantial health benefits to patients. Headquartered in New Haven, Connecticut, with a supporting facility at the University of Connecticut’s Technology Incubation Program, Rallybio continues to strive for innovation. "Our success hinges on mobilizing the best people, partners, and science," said Rallybio’s leadership. "With this funding, we are more empowered than ever to create fearless paths and deliver truly transformational therapies to those in need." This milestone not only underscores the growing confidence in Rallybio's vision but also reinforces the company’s commitment to shaping the future of healthcare for underserved populations.